A case of lymphomatoid granulomatosis with central nervous system involvement successfully treated with IFNα

Int J Hematol. 2021 Oct;114(4):502-508. doi: 10.1007/s12185-021-03178-8. Epub 2021 Jun 22.

Abstract

Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disease affecting mainly extranodal sites such as the lung, central nervous system (CNS), skin, kidney, and liver. We report a case of low-grade LYG involving the CNS that was successfully treated with interferon alpha (IFNα). A 69-year-old woman developed necrotic erythema of the skin and was initially diagnosed with pyoderma gangrenosum based on skin biopsy. She showed a limited response to prednisolone. Approximately 6 months after the initial onset, low-grade LYG was diagnosed after detection of CNS lesions on brain biopsy. The whole blood EBV-DNA load determined by real-time polymerase chain reaction was slightly elevated. Two months into IFNα therapy, skin and CNS lesions had responded favorably and the EBV-DNA load decreased. IFNα plays an important role in treatment of LYG through its antiproliferative, immunomodulatory, and anti-EBV effects. To our knowledge, this is the first case report of successful treatment with IFNα in Japan. Further investigation is necessary to determine optimal use of IFNα for LYG.

Keywords: Central nervous system; Epstein–Barr virus; Interferon alpha; Lymphomatoid granulomatosis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Biomarkers
  • Biopsy
  • Central Nervous System Neoplasms / diagnosis*
  • Central Nervous System Neoplasms / drug therapy*
  • Central Nervous System Neoplasms / etiology
  • Clonal Evolution
  • Female
  • Humans
  • Immunohistochemistry
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Lymphomatoid Granulomatosis / diagnosis*
  • Lymphomatoid Granulomatosis / drug therapy*
  • Lymphomatoid Granulomatosis / etiology
  • Magnetic Resonance Imaging
  • Symptom Assessment
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Biomarkers
  • Interferon-alpha